PMID- 23158281
OWN - NLM
STAT- MEDLINE
DCOM- 20130905
LR  - 20181202
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 92
IP  - 30
DP  - 2012 Aug 14
TI  - [Protective effects of rosiglitazone intervention on monocrotaline-induced 
      pulmonary arterial hypertension in rats and related inflammatory mechanisms].
PG  - 2144-7
AB  - OBJECTIVE: To investigate the protective effects of rosiglitazone intervention on 
      monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rats and the 
      possible mechanisms. METHODS: Thirty-two Sprague-Dawley rats were randomly 
      divided into 4 groups: control group with a subcutaneous injection of normal 
      saline. PAH group, high-dose and low-dose rosiglitazone intervention groups all 
      with a subcutaneous injection of MCT and then gastric infusion of normal saline 
      (1.5 ml/d), rosiglitazone (5, 2.5 mg.kg(-1)xd(-1)). At Day 21, the mean pulmonary 
      arterial pressure (mPAP) was detected by right heart catheter. Then rats were 
      sacrificed and their lungs extracted. Perivascular inflammation was scored with 
      the subjective scale of 0 to 4. The tunica media thickness percentage of small 
      pulmonary arteries (WT%) of rats was calculated. Interleukin 6 (IL-6), tumor 
      necrosis factor alpha (TNF-alpha) and monocyte chemotactic protein 1 (MCP-1) of lung 
      tissue were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS: 
      Compared with the PAH group ((37 +/- 5) mm Hg (1 mm Hg = 0.133 kPa), 45.5% +/- 5.5%), 
      the mPAP and WT% of the high-dose ((27 +/- 4) mm Hg, 13.1% +/- 3.9%) and low-dose 
      ((28 +/- 4) mm Hg, 16.7% +/- 1.7%) rosiglitazone intervention group were 
      significantly lower (P < 0.01), but were still higher than those of the control 
      group ((17 +/- 3) mm Hg, 8.9% +/- 2.3%) (P < 0.05 or P < 0.01). The perivascular 
      inflammation score and levels of IL-6, TNF-alpha, MCP-1 of high-dose and low-dose 
      rosiglitazone intervention groups were significantly lower than those of the PAH 
      group (P < 0.01). Compared with the low-dose rosiglitazone intervention group, 
      all the above indices of the high-dose rosiglitazone intervention group appeared 
      much lower (P > 0.05). CONCLUSION: The protective effects of rosiglitazone 
      against MCT-induced PH are correlated with drug dose and may be due to the 
      inhibition of inflammation.
FAU - Wang, Xiao-fang
AU  - Wang XF
AD  - Department of Respiratory Medicine, Beijing Jishuitan Hospital, Beijing 100035, 
      China.
FAU - Lu, Wei-xuan
AU  - Lu WX
FAU - Guo, Jun
AU  - Guo J
FAU - Li, Guo
AU  - Li G
FAU - Zhang, Yun-jian
AU  - Zhang YJ
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 73077K8HYV (Monocrotaline)
SB  - IM
MH  - Animals
MH  - Hypertension, Pulmonary/chemically induced/*pathology/*physiopathology
MH  - Inflammation/metabolism
MH  - Male
MH  - Monocrotaline/*adverse effects
MH  - Pulmonary Artery/pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Rosiglitazone
MH  - Thiazolidinediones/*pharmacology
EDAT- 2012/11/20 06:00
MHDA- 2013/09/06 06:00
CRDT- 2012/11/20 06:00
PHST- 2012/11/20 06:00 [entrez]
PHST- 2012/11/20 06:00 [pubmed]
PHST- 2013/09/06 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2012 Aug 14;92(30):2144-7.